Online inquiry

IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2734MR)

This product GTTS-WQ2734MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2734MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12705MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ5666MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ2492MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ2234MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aVWF81
GTTS-WQ10787MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ13011MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ254MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ14225MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG-6107
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW